Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dolutegravir in Pregnant HIV Mothers and Their Neonates

Trial Profile

Dolutegravir in Pregnant HIV Mothers and Their Neonates

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dolutegravir (Primary) ; Efavirenz
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms DolPHIN-2
  • Most Recent Events

    • 10 Nov 2023 Status changed from active, no longer recruiting to completed.
    • 26 Oct 2022 Results from DolPHIN-2, ADVANCE, NAMSAL and VISEND, comparing rates of virological failure (VF)and re-suppression in four randomised trials of dolutegravir (DTG), efavirenz (EFV) and protease inhibitors , presented at the 16th International Congress on Drug Therapy and HIV Infection
    • 26 Oct 2022 Data of adverse birth outcomes from 5 studies DolPHIN-1, DolPHIN-2, ADVANCE, NAMSAL and IMPAACT-2010 were presented at the 16th International Congress on Drug Therapy and HIV Infection.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top